Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Champions Oncology, Inc.NASDAQ: CSBR

Income Tax Expense · Q3 FY2026 · quarter ended Jan 2026

Income tax expense growth accelerates

Q3 FY2026 income tax expense of $42K rose 82.6% year over year, ahead of the -111.5% change in trailing-twelve-month income tax expense. Sequentially, it rose 133.3% from the prior quarter.

Context

  • Income tax expense amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +82.6% holds above the trailing-twelve-month pace of -111.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
$42K+133.3% QoQ
Last fiscal yearApr 2025
-$75K-134.4% YoY
LTMJan 2026
-$55K-111.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.6%——
1 year-134.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(75K) USD
Year-over-year change
-134.4%

Income Tax Expense vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -111.5% is the 6th highest of 7, against a peer median of +61.9%.
  • Income tax expense amounts to 0.1% of revenue for CSBR, versus a peer median of 0.1%.
CSBR Competitors
Income Tax Expense for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$21.85M USD+480.1%+383.6%—
CNTBConnect Biopharma Holdings LimitedFY2025$197K USD-11.7%-12.9%307.8%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$31K USD+186.1%+37.2%0.1%
IFRXInflaRx N.V.LTM Mar 2026€12.28K EUR+135.4%—41.9%
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD———
CSBRChampions Oncology, Inc.LTM Jan 2026-$55K USD-111.5%—0.1%
STROSutro Biopharma, Inc.LTM Mar 2026-$115K USD-104.9%—0.1%
IMAImageneBio IncLTM Mar 2026-$325K USD-312.4%——
Peer median (excluding CSBR) —+61.9%+37.2%0.1%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.